Migracor (Sumatriptan)

Sumatriptan, the active ingredient in Migracor, is a Triptan presented as a nasal spray for nasal use. It is indicated for the acute treatment of migraine attacks in adults, providing rapid relief of headache pain and associated symptoms. The formulation delivers the drug directly to the nasal mucosa, allowing faster absorption compared with oral tablets.

GNH USA supplies Migracor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Migracor (sumatriptan) belongs to the triptan class and is used for acute migraine and related headache disorders. - Migraine: provides rapid relief of headache pain, photophobia, phonophobia and nausea during an acute attack. - Migraine with aura: alleviates headache and associated neurological symptoms when they occur. - Cluster headache: aborts acute cluster headache episodes in patients who respond to triptans.

Sumatriptan nasal spray may cause a range of adverse reactions. Monitoring and patient counseling are recommended.

Common Side Effects: - Taste disturbance: unpleasant metallic or bitter taste in the mouth. - Nasal irritation: burning, stinging or itching of the nasal mucosa. - Throat irritation: soreness or dryness after administration. - Dizziness: transient light‑headedness or vertigo. - Nausea: mild upset stomach following use. - Somnolence: feeling unusually sleepy or fatigued.

Serious or Rare Side Effects: - Chest pain or tightness: possible cardiac ischemia, especially in patients with cardiovascular risk. - Serotonin syndrome: agitation, hyperthermia, tremor when combined with other serotonergic agents. - Severe allergic reaction: rash, swelling, difficulty breathing indicating anaphylaxis. - Hypertension: sudden increase in blood pressure. - Coronary vasospasm: constriction of coronary arteries leading to myocardial ischemia.

Before prescribing Migracor, clinicians should consider several safety factors. - Cardiovascular disease: avoid use in patients with known coronary artery disease or uncontrolled hypertension. - History of stroke or TIA: contraindicated due to risk of cerebrovascular events. - Concomitant MAO inhibitors: avoid co‑administration as it may increase serotonergic effects. - Pregnancy: safety not established; use only if potential benefit outweighs risk. - Serotonergic drugs: assess risk of serotonin syndrome when combined with SSRIs, SNRIs, or linezolid. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Sumatriptan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergot alkaloids: additive vasoconstriction may precipitate cardiovascular events. - Certain antihypertensives (e.g., propranolol): may increase sumatriptan plasma levels.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: monitor for signs of serotonin syndrome. - Linezolid and tramadol: combined serotonergic activity warrants observation. - Dextromethorphan: may enhance serotonergic effects, requiring caution.